SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards as investors express concerns about its correlation to Bitcoin's price and the dilutive effect of share issuances for further BTC acquisitions. The community is actively debating the company's business model and potential outcomes post-earnings, with some fearing a significant drop. Concerns about a potential collapse, comparisons to past financial downturns, and the influence of short sellers are also prevalent in discussions.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards as investors react to increased AI spending plans and a large one-time tax charge, overshadowing otherwise positive earnings results. Despite a record-breaking bond offering, the community is debating whether this dip represents a buying opportunity or reflects deeper concerns about Meta's capital expenditures. Some traders are closely watching key support levels and potential for a rebound, while others express skepticism about the long-term profitability of Meta's AI investments.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending as investors brace for its earnings report, with the central focus being ad revenue and AI partnerships. Community members are weighing the potential for a significant post-earnings move, drawing comparisons to META's recent performance, while also highlighting high short interest as a possible catalyst for a squeeze. Some traders express caution about the stock's valuation and potential for a selloff if earnings disappoint.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending downwards, with the community expressing concerns about recent price action and continued stock dilution; some are questioning the company's overall strategy and the credibility of bullish forecasts, while others remain optimistic about the long-term potential of Ethereum and BMNR's accumulation strategy.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amid buyout speculation and renewed interest from SpaceX, driving community excitement about a potential bidding war. The community is buzzing about possible high buyout figures and the implications for existing partnerships, including the Apple deal. Discussions also involve Globalstar's spectrum value and potential combinations with other industry players.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending as investors anticipate upcoming earnings, with some expecting a significant move in either direction. Community members are actively discussing potential outcomes and strategizing based on technical analysis and unusual options activity. The broader tech sector and potential AI developments remain a key focus for Apple's future growth.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid speculation of a potential acquisition, fueled by a recent report suggesting the company is in talks for a significant deal. The community is actively discussing potential buyout prices and speculating on which pharmaceutical company could be the acquirer, with some pointing to the company's oncology pipeline as a key attraction. Despite the positive price movement, some investors remain cautious, citing upcoming earnings and potential legal liabilities.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors gear up for earnings, with debates focusing on AWS growth and its potential impact on the stock's direction. The community is weighing the impact of AI investments and recent layoffs, while considering Amazon's overall standing within the broader tech landscape. Some anticipate a post-earnings surge, while others brace for a potential downturn, highlighting the uncertainty surrounding the report.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending downwards as investors react to concerns about slowing revenue growth and declining traffic, particularly among younger, lower-income consumers. The community is discussing the impact of these trends on the company's future, with some suggesting the need for strategic changes and others viewing the dip as a buying opportunity. There is also debate around the value proposition offered by Chipotle compared to competitors amidst rising costs.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending as the community discusses a potential short squeeze and re-evaluation after a robust third quarter and raised FY25 EBITDA guidance, with some anticipating analyst upgrades and significant price movement. Bullish investors are expressing confidence in the company's fundamentals, while others debate potential resistance levels and optimal strategies. High trading volume and positive cash flow reports are also contributing to the heightened interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

Nurix Therapeutics shares fell more than 6% in after-hours trading on Thursday after the biotech firm reported a wider quarterly loss and lower revenue, reflecting higher research spending and changes in collaborations.In the third fiscal quarter ended Aug. 31, the San Francisco–based company posted a net loss of $86.4 million, or $1.03 a share, versus a loss of $49 million, or $0.67 a share, a year earlier.&nbsp;Revenue dropped to $7.9 million from $12.6 million, with income from its collaboration with Sanofi down following the expiration of the initial research period for certain targets. The decrease was partly offset by a higher percentage of completion of performance obligations related to its partnership with Pfizer.Research and development costs increased to $86.1 million from $55.5 million a year ago, mainly due to higher clinical, manufacturing and consulting costs related to increased enrollment in ongoing studies and preparation for late-stage trials.Nurix said it plans to launch pivotal trials next year for its BTK degrader bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The program will include a single-arm study for potential accelerated approval and a randomized Phase 3 trial for full approval.The company reported $428.8 million in cash and marketable securities at the end of the quarter and said it had enough capital to continue funding its programs and development partnerships with Gilead, Sanofi and Pfizer.Oppenheimer maintained an 'Outperform' rating on Nurix Therapeutics after lowering its price target to $28 from $30 following its results. The brokerage said shares have rebounded as investors become more comfortable with the regulatory strategy for bexobrutideg, particularly its prospects for accelerated approval.Oppenheimer noted that Nurix has been having ongoing discussions with the FDA under the drug’s Fast Track designation, and while management has continued to say publicly that accelerated approval will be a review issue, changes in the company’s latest corporate presentation suggest the FDA is&nbsp;on board with the plan, the firm added.One user noted that research and development spending had “gone way up,” suggesting it could shorten the company’s cash runway, but added there was still time to buy before shares begin to move higher ahead of pivotal bexobrutideg data.<stembedurl>https://stocktwits.com/oaksapollo/message/631728185</stembedurl>Another user said they had increased their position in Nurix, adding that they plan to keep buying as long as the stock remains below $10, and argued that bexobrutideg alone justifies the company’s roughly $685 million market capitalization.<stembedurl>https://stocktwits.com/oaksapollo/message/630831468</stembedurl><a href="https://stocktwits.com/symbol/NRIX">Nurix’s stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nurix’s stock (NRIX) has declined 42% so far in 2025. (Photo credit: Getty Images)

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip

Oppenheimer cut its price target to $28 from $30 but kept a bullish view, citing FDA discussions and investor confidence in its Bexo program.

Equity

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -22.62% and -57.71%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock?

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Nurix Therapeutics jumped on Wednesday after the biotech company reported stronger-than-expected results for the second quarter (Q2), bolstered by payments related to development milestones with both Sanofi and Gilead Sciences.The <a href="https://stocktwits.com/symbol/NRIX">Nurix Therapeutics stock</a> rose 7.9% on Wednesday and climbed another 13.9% after-hours.The company reported a net loss of $0.52 per share for the quarter ended May 31, above analyst estimates of a loss of $0.74 per share.&nbsp;Nurix also recorded revenue of $44.1 million, exceeding estimates of $17.5 million.&nbsp;A large chunk of that came from a $30 million license payment from Sanofi and a $5 million milestone tied to a Gilead-supported clinical program.Spending also increased as the company pushed ahead with its lead drug candidates.&nbsp;Research and development costs climbed to $78.1 million, up from $48.9 million a year earlier, while administrative expenses rose to $14.3 million from $11.7 million.The company shared new data from an early-stage trial of bexobrutideg, a BTK degrader it’s developing for certain blood cancers.&nbsp;Among patients with relapsed or treatment-resistant chronic lymphocytic leukemia, the treatment showed a response rate of 80.9%, with no serious heart issues or other safety red flags reported.Nurix finished the quarter with $485.8 million in cash and investments. The figure doesn’t include an additional $19 million it received shortly after the quarter ended from its partners.Looking ahead, the company plans to start late-stage trials of bexobrutideg later this year.&nbsp;It’s also expecting more clinical updates from other programs in its pipeline, including NX-2127 and NX-1607.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.One user noted that Nurix’s Q2 loss of $0.52 per share came in about 30% better than analyst expectations, and added that the stock could see another strong session tomorrow.<stembedurl>https://stocktwits.com/LongTrainRunning/message/620401421</stembedurl>Nurix Therapeutics’ stock has declined 32.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nurix Therapeutics (NRIX) reported stronger-than-expected results for the second quarter/ Photo credit: Getty Images

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year. 

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Nurix Therapeutics (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's  What You Should Know

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 143.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Nurix Therapeutics Inc

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

NRIX
Nurix Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRIX News

NRIXNurix Therapeutics Inc